These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222 [TBL] [Abstract][Full Text] [Related]
26. [Pharmacotherapy in ovarian carcinoma]. Pfisterer J; Du Bois A MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419 [TBL] [Abstract][Full Text] [Related]
27. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. McGuire WP J Clin Oncol; 2009 Oct; 27(28):4633-4. PubMed ID: 19704055 [No Abstract] [Full Text] [Related]
28. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
32. A new standard of care for treatment of ovarian cancer. Piccart MJ; Du Bois A; Gore ME; Neijt JP; Pecorelli S; Pujade-Lauraine E Eur J Cancer; 2000 Jan; 36(1):10-2. PubMed ID: 10741290 [No Abstract] [Full Text] [Related]
33. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies]. Yamazaki S; Sekine I; Saijo N Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372 [TBL] [Abstract][Full Text] [Related]
34. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Parmar MK; Ledermann JA; Colombo N; du Bois A; Delaloye JF; Kristensen GB; Wheeler S; Swart AM; Qian W; Torri V; Floriani I; Jayson G; Lamont A; Tropé C; Lancet; 2003 Jun; 361(9375):2099-106. PubMed ID: 12826431 [TBL] [Abstract][Full Text] [Related]
35. [Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer]. Gorbunova VA; Khokhlova SV; Besova NS; Orel NF; Kuznetsov VV; Bliumenberg AG; Smirnova NB; Chekalova MA; Sinitsyna ME; Poddubnyĭ BK Vopr Onkol; 2001; 47(5):1-6. PubMed ID: 11799946 [No Abstract] [Full Text] [Related]
36. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer. Limat S; Woronoff-Lemsi MC; Menat C; Madroszyk-Flandin A; Merrouche Y Pharmacoeconomics; 2004; 22(10):633-41. PubMed ID: 15244489 [TBL] [Abstract][Full Text] [Related]
37. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839 [TBL] [Abstract][Full Text] [Related]
38. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [TBL] [Abstract][Full Text] [Related]